Global Gaucher Disease Market, Type (Gaucher Disease Type 1, Gaucher Disease Type 2, Gaucher Disease Type 3, Others), Diagnosis (Physical Exam, Blood Tests, Imaging Tests, Preconception Screening and Prenatal Testing, Others), Treatment (Surgery, Medication, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Gaucher disease is a hereditary metabolic disease in which glucocerebroside, a form of fat (lipid), is unable to breakdown. Glucocerebrosidase is an enzyme that breaks down and reprocesses glucocerebroside in the human body. Gaucher disease is caused by mutations in the GBA gene, which results in very low levels of the glucocerebrosidase enzyme, which causes glucocerebroside breakdown to be slow. Gaucher disease is characterized as one of three types: type 1, type 2, or type 3. Gaucher disease is classified into type 1, type 2, and type 3. Type 1 is the most frequent, whereas type 2 and type 3 are less common.
Data Bridge Market Research analyses that the Gaucher disease market was valued at USD 1.54 billion in 2021 and is expected to reach USD 1.88 billion by 2029, registering a CAGR of 2.50% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Gaucher Disease Type 1, Gaucher Disease Type 2, Gaucher Disease Type 3, Others), Diagnosis (Physical Exam, Blood Tests, Imaging Tests, Preconception Screening and Prenatal Testing, Others), Treatment (Surgery, Medication, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Novartis AG (Switzerland), Johnson & Johnson Private Limited (U.S.), Teva Pharmaceutical Industries Ltd. (Ireland), Merck and Co., Inc. (U.S.), Allergan (Ireland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Sanofi (France), Merck KGaA (Germany), Abbott (U.S.), Boehringer Ingelheim International GmbH. (Germany), Takeda Pharmaceutical Company Limited (Japan), Amicus Therapeutics, Inc. (U.S.), Moderna, Inc. (U.S.),Greenovation Biotech GmbH (Germany), Biomarin (U.S.), JCR Pharmaceuticals Co., Ltd (Japan), ISU ABXIS (South Korea), Idorsia Pharmaceuticals Ltd (Switzerland), AVROBIO, Inc. (U.S.), Resverlogix Corp. (Canada), Enzyvant (U.S.), CHIESI Farmaceutici SpA (Italy)
|
|
Market Opportunities
|
|
Market Definition
Gaucher disease is caused by an accumulation of fatty substances in your organs, especially your spleen and liver. These organs increase as a result of this, which can have an impact on their function. While Gaucher disease has no cure, there are a number of treatments that can help manage symptoms, avoid irreparable damage, and enhance quality of life. The defective enzyme is replaced with artificial enzymes in enzyme replacement therapy. Iglucerase, velaglucerase alfa and taliglucerase are the three ERT medicines currently approved by the FDA (Elelyso). Transfusions of blood products for severe anaemia and bleeding; analgesics for bone pain; joint replacement surgery for chronic pain alleviation and function restoration; and anti-bone resorption medicines, calcium, and vitamin D for osteoporosis
Gaucher Disease Market Dynamics
Drivers
- Rising prevalence of lysosomal disease
The rising prevalence of lysosomal disease will act as a major driver that will result in the expansion of the market's growth rate. Lysosomal storage disorders are inherited metabolic disorders marked by an abnormal accumulation of numerous harmful chemicals in the body's cells as a result of enzyme shortages. For those with Gaucher disease type I, enzyme replacement therapy (ERT) has been shown to be successful. Anemia and low platelet counts have improved, liver and spleen enlargement has decreased significantly, and skeletal abnormalities have improved. Individuals with Gaucher disease types II and III who get ERT also see improvements in these systemic signs.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of Gaucher disease market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, surging number of government initiatives to spread awareness and rising adoption rate of early diagnosis will result in the expansion of Gaucher disease market. Along with this, rising level of disposable income and increasing the need for better disease treatment options will enhance the market's growth rate.
Opportunities
- Rise in RandD activities
The market's growth is fueled by growing number of research and development activities. This will provide beneficial opportunities for the Gaucher disease market growth. For instance, biodistribution studies in LSD models provide evidence for the theory that the RTB-lectin transports corrective doses of enzymes across the blood–brain barrier for the treatment of central nervous system pathologies, according to researchers from BioStrategies LC, State University (U.S.).
Moreover, the market's growth is fueled by investment to develop advanced technologies and increase the number of emerging markets. These factors will provide beneficial opportunities for the Gaucher disease market growth.
Restraints/Challenges
On the other hand, the high cost associated with the treatment will obstruct the growth rate of Gaucher disease market during the forecast period of 2022-2029. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the Gaucher disease market. Additionally, lack of awareness among people and poor reimbursement policies will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.
This Gaucher disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Gaucher disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Gaucher disease is a recessive gene dominant disease that has a wide range of clinical manifestations. It is the most prevalent lysosomal storage disorder, with a prevalence of 1 in every 50,000 live births. The fatal perinatal type of the disease is the most severe. Gaucher disease is thought to manifest itself most strongly in the Jewish population of Eastern and Central Europe, affecting one out of every 450 persons and resulting in one out of every ten disease carriers within the descend.
Gaucher disease market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Global Gaucher Disease Market Scope
The Gaucher disease market is segmented on the basis of type, diagnosis, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Diagnosis
- Physical Exam
- Blood Tests
- Imaging Tests
- Preconception Screening and Prenatal Testing
- Others
Type
- Gaucher Disease Type 1
- Gaucher Disease Type 2
- Gaucher Disease Type 3
- Others
Treatment
- Surgery
- Spleen removal
- Bone-marrow transplant
- Others
- Medication
- Enzyme replacement therapy
- Iglucerase
- Velaglucerase alfa
- Taliglucerase
- Osteoporosis drugs
- Glucosylceramide synthase inhibitors
- Others
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Gaucher Disease Market Regional Analysis/Insights
The Gaucher disease market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Gaucher disease market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the Gaucher disease market because of the rising healthcare expenditure and highly sophisticated medical facilities in this region. Additionally, growing focus of major key players in research and development activities for Gaucher disease will further propel the market's growth rate in this region.
Asia-Pacific is expected to grow significantly during the forecast period of 2022-2029 due to presence of key market players in this region. Also, the development of healthcare infrastructure and high diagnostic rate will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Gaucher Disease Market Share Analysis
The Gaucher disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Gaucher disease market.
Some of the major players operating in the Gaucher disease market are:
- Novartis AG (Switzerland)
- Johnson and Johnson Private Limited (U.S.)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Merck and Co., Inc. (U.S.)
- Allergan (Ireland)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Sanofi (France)
- Merck KGaA (Germany)
- Abbott (U.S.)
- Boehringer Ingelheim International GmbH. (Germany)
- Takeda Pharmaceutical Company Limited (Japan)
- Amicus Therapeutics, Inc. (U.S.)
- Moderna, Inc. (U.S.)
- Greenovation Biotech GmbH (Germany)
- Biomarin (U.S.)
- JCR Pharmaceuticals Co., Ltd (Japan)
- ISU ABXIS (South Korea)
- Idorsia Pharmaceuticals Ltd (Switzerland)
- AVROBIO, Inc. (U.S.)
- Resverlogix Corp. (Canada)
- Enzyvant (U.S.)
- CHIESI Farmaceutici SpA (Italy)
SKU-